G. Roosendaal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
G. Roosendaal has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
F. P. J. G. Lafeber
Department of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
1 shared publication- F. P. J. G. Lafeber
Department of Rheumatology & Clinical Immunology, University Medical Center (UMC) Utrecht, Utrecht, The Netherlands
1 shared publication F. P. Lafeber
University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publicationN. W. D. Jansen
Department of Hematology and Van Creveld Clinic
1 shared publication- Roger E. G. Schutgens
Van Creveldkliniek, Center for Benign Hematology, Thrombosis and Hemostasis, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication
Latest Publications
- 29 September 2008
- Published by Wiley in Haemophilia
- Vol. 14 (s6) , 4-10
Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment
Summary. In a case of massive bleeding, the possibility of puncturing the joint can be considered to reduce the total load of intra‐articular blood, and thus the total load of iron which, in time, can be found in the synovium with devastating long‐term effects. Subsequent initiation of prophylaxis, still very early in life, might be more beneficial for the preservation of joints. Thus, it might be argued that the initiation of primary prophylaxis should be based on joint haemorrhage history rather than age and, according to some authors, preferably after the bleed in a single joint. The high cost of recombinant factor VIII may make widespread acceptance of prophylaxis impractical. Thus, beneficial results should be balanced with cost considerations. In this balance of treatment cost and efficacy, it must be taken into account that improperly treated haemophilia patients make great demands on healthcare systems (in terms of costs) because of their need for additional treatments such as expensive joint replacement surgery. However, where resources are limited, it can be argued that prophylaxis may be stopped in adulthood, in a certain proportion of all adult patients, with acceptable consequences for orthopaedic outcome in the long term. By doing so, limited amounts of clotting factor can be used for young patients with optimal cost effectiveness.
- 29 September 2008
- Published by Wiley in Haemophilia
- Vol. 14 (s6) , 4-10
Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment
Summary. In a case of massive bleeding, the possibility of puncturing the joint can be considered to reduce the total load of intra‐articular blood, and thus the total load of iron which, in time, can be found in the synovium with devastating long‐term effects. Subsequent initiation of prophylaxis, still very early in life, might be more beneficial for the preservation of joints. Thus, it might be argued that the initiation of primary prophylaxis should be based on joint haemorrhage history rather than age and, according to some authors, preferably after the bleed in a single joint. The high cost of recombinant factor VIII may make widespread acceptance of prophylaxis impractical. Thus, beneficial results should be balanced with cost considerations. In this balance of treatment cost and efficacy, it must be taken into account that improperly treated haemophilia patients make great demands on healthcare systems (in terms of costs) because of their need for additional treatments such as expensive joint replacement surgery. However, where resources are limited, it can be argued that prophylaxis may be stopped in adulthood, in a certain proportion of all adult patients, with acceptable consequences for orthopaedic outcome in the long term. By doing so, limited amounts of clotting factor can be used for young patients with optimal cost effectiveness.
- 24 November 2007
- Vol. 151 (47) , 2606-8
[Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
A recent publication stated that the cost of prophylactic clotting factor replacement therapy to prevent joint damage in patients with haemophilia is USD 300,000 per patient per year. Therefore, despite the relatively small number of patients with severe haemophilia, the disease has an important socioeconomic impact. Joint damage is the most frequent and most debilitating comorbidity of haemophilia and can be prevented by adequate prophylactic treatment. But when and how should prophylaxis be started? The aforementioned study provides thorough evidence that prophylaxis is clinically beneficial despite its high cost. A reasonable approach is to start individualised prophylactic treatment after the first episode of joint bleeding early in life, because prophylaxis will not prevent progression of established joint disease evident after multiple bleeding episodes.
- 24 November 2007
- Vol. 151 (47) , 2606-8
[Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
A recent publication stated that the cost of prophylactic clotting factor replacement therapy to prevent joint damage in patients with haemophilia is USD 300,000 per patient per year. Therefore, despite the relatively small number of patients with severe haemophilia, the disease has an important socioeconomic impact. Joint damage is the most frequent and most debilitating comorbidity of haemophilia and can be prevented by adequate prophylactic treatment. But when and how should prophylaxis be started? The aforementioned study provides thorough evidence that prophylaxis is clinically beneficial despite its high cost. A reasonable approach is to start individualised prophylactic treatment after the first episode of joint bleeding early in life, because prophylaxis will not prevent progression of established joint disease evident after multiple bleeding episodes.
- 27 April 2006
- Published by Wiley in Haemophilia
- Vol. 12 (s3) , 117-121
Pathogenesis of haemophilic arthropathy
Summary. The pathogenetic mechanism of haemophilic arthropathy is multifactorial and includes degenerative cartilage‐mediated and inflammatory synovium‐mediated components. Intra‐articular blood first has a direct effect on cartilage, as a result of the iron‐catalysed formation of destructive oxygen metabolites (resulting in chondrocyte apoptosis), and subsequently affects the synovium, in addition to haemosiderin‐induced synovial triggering. Both processes occur in parallel, and while they influence each other they probably do not depend on each other. This concept resembles degenerative joint damage as found in osteoarthritis as well as inflammatory processes in rheumatoid arthritis. These processes finally result in a fibrotic and destroyed joint.
- 27 April 2006
- Published by Wiley in Haemophilia
- Vol. 12 (s3) , 117-121
Pathogenesis of haemophilic arthropathy
Summary. The pathogenetic mechanism of haemophilic arthropathy is multifactorial and includes degenerative cartilage‐mediated and inflammatory synovium‐mediated components. Intra‐articular blood first has a direct effect on cartilage, as a result of the iron‐catalysed formation of destructive oxygen metabolites (resulting in chondrocyte apoptosis), and subsequently affects the synovium, in addition to haemosiderin‐induced synovial triggering. Both processes occur in parallel, and while they influence each other they probably do not depend on each other. This concept resembles degenerative joint damage as found in osteoarthritis as well as inflammatory processes in rheumatoid arthritis. These processes finally result in a fibrotic and destroyed joint.